2010年6月，美国FDA批准盐酸美金刚(memantine hydroehloride)28mg缓释胶囊NamendaX日，用于一日1次口服治疗中至重度阿尔茨海默病患者。
NAMENDA XR CAP TITRATION PACK 盐酸美金刚胶囊
里面含 Contains 28 capsules(7粒x7mg, 7粒x14mg, 粒7x21mg, 7粒x28mg)
NAMENDA XR CAP 7MG 30
NAMENDA XR CAP 14MG 30
NAMENDA XR CAP 21MG 30
Generic Name and Formulations:
Memantine HCl 7mg, 14mg, 21mg, 28mg; ext-rel caps.

Company:
Forest Laboratories
Indications for NAMENDA XR:
Moderate-to-severe dementia of the Alzheimer's type.

Adult:
Do not divide doses. Swallow whole or may open caps and sprinkle on applesauce, then consume entire contents. Initially 7mg once daily; titrate at intervals of at least 1 week in increments of 7mg to target dose of 28mg once daily. Max 28mg once daily. Severe renal impairment (CrCl 5–29mL/min): titrate to target dose of 14mg/day. Switching from immediate-release tabs: give XR caps the day after last dose of immediate-release tabs; see full labeling.

Children:
Not established.

See Also:
NAMENDA

NAMENDA ORAL SOLUTION

Pharmacological Class:
N-methyl-D-aspartate (NMDA) receptor antagonist.

Warnings/Precautions:
Severe hepatic impairment. Alkalinized urine (eg, renal tubular acidosis, severe UTI) increases memantine serum levels. Seizure disorder. Pregnancy (Cat.B). Nursing mothers.

Interactions:
Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). May affect or be affected by renally-excreted drugs (eg, triamterene, HCTZ, metformin, cimetidine, nicotine, ranitidine, quinidine). Plasma levels may be increased by urinary alkalinizers.

Adverse Reactions:
Headache, dizziness, confusion, diarrhea, constipation, hypertension, pain, somnolence, hallucination, urinary disorders, dyspnea.

Metabolism:
Hepatic (partial).

Elimination:
Renal.

How Supplied:
Tabs—60; Titration Pak (28 x 5mg + 21 x 10mg)—1; Oral soln—360mL; XR caps 7mg, 21mg—30; 14mg, 28mg—30, 90; XR Titration Pak (7 x 7mg + 7 x 14mg + 7 x 21mg + 7 x 28mg)—